Bokhman Redux: Endometrial cancer “types” in the 21st century

Gynecologic Oncology

Volumn 144, Issue 2, 2017, Pages 243-249

  Suarez, Adrian A ^a   Felix, Ashley S ^b   Cohn, David E ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer risk; Endometrial cancer; Endometrial carcinoma; Metabolic syndrome; Obesity; Risk factor

Indexed keywords

HORMONE;

CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; DATA BASE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EPIDEMIOLOGICAL DATA; FOLLOW UP; GENE; GENE MUTATION; HISTOLOGY; HUMAN; METABOLIC SYNDROME X; MICROSATELLITE INSTABILITY; MODEL; OBESITY; POLE GENE; PRIORITY JOURNAL; PTEN GENE; SHORT SURVEY; TUMOR SUPPRESSOR GENE; CLASSIFICATION; COMPLICATION; ENDOMETRIUM TUMOR; FEMALE; GENETICS; MORTALITY; PATHOLOGY; TUMOR INVASION;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; OBESITY;

EID: 85007573029     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.12.010     Document Type: Short Survey

References (66)

1. [1] Bokhman, J.V., Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15 (1983), 10–17.
2. [2] Novak, E., Yui, E., Relation of endometrial hyperplasia to adenocarcinoma of the uterus. Am. J. Obstet. Gynecol. 32 (1936), 674–698.
3. [3] Hertig, A.T., Sommers, S.C., Genesis of endometrial carcinoma; study of prior biopsies. Cancer 2 (1949), 946–956.
4. [4] Moss, W.T., Common peculiarities of patients with adenocarcinoma of the endometrium with special reference to obesity, body build, diabetes and hypertension. Am. J. Roentgenol. Radium. Ther. 58 (1947), 203–210.
5. [5] Randall, J.H., Mirick, D.F., Wieben, E.E., Endometrial carcinoma. Am. J. Obstet. Gynecol. 61 (1951), 596–602.
6. [6] Randall, J.H., Goddard, W.B., A study of 531 cases on endometrial carcinoma. Surg. Gynecol. Obstet. 103 (1956), 221–226.
7. [7] Javert, C.T., Renning, E.L., Endometrial cancer; survey of 610 cases at Woman's Hospital (1919–1960). Cancer 16 (1963), 1057–1071.
8. [8] Sarafidis, P.A., Nilsson, P.M., The metabolic syndrome: a glance at its history. J. Hypertens. 24 (2006), 621–626.
9. [9] Grodin, J.M., Siiteri, P.K., MacDonald, P.C., Source of estrogen production in postmenopausal women. J. Clin. Endocrinol. Metab. 36 (1973), 207–214.
10. [10] Schindler, A.E., Ebert, A., Friedrich, E., Conversion of androstenedione to estrone by human fat tissue. J. Clin. Endocrinol. Metab. 35 (1972), 627–630.
11. [11] Forney, J.P., Milewich, L., Chen, G.T., et al. Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia. J. Clin. Endocrinol. Metab. 53 (1981), 192–199.
12. [12] Silverberg, S.G., New aspects of endometrial carcinoma. Clin. Obstet. Gynecol. 11 (1984), 189–208.
13. [13] Lauchlan, S.C., Tubal (serous) carcinoma of the endometrium. Arch. Pathol. Lab. Med. 105 (1981), 615–618.
14. [14] Hendrickson, M., Ross, J., Eifel, P., Martinez, A., Kempson, R., Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6 (1982), 93–108.
15. [15] Berthelsen, H.G., Svane, H.A., Cancer of the endometrium and hyperestrinism; two different modes of origin of endometrial cancer. Dan. Med. Bull. 3 (1956), 236–239.
16. [16] Beckner, M.E., Mori, T., Silverberg, S.G., Endometrial carcinoma: non-tumor factors in prognosis. Int. J. Gynecol. Pathol. 4 (1985), 131–145.
17. [17] Anderson, B., Connor, J.P., Andrews, J.I., Davis, C.S., Buller, R.E., Sorosky, J.I., Benda, J.A., Obesity and prognosis in endometrial cancer. Am. J. Obstet. Gynecol. 174 (1996), 1171–1178.
18. [18] Everett, E., Tamimi, H., Greer, B., et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol. Oncol. 90 (2003), 150–157.
19. [19] Münstedt, K., Wagner, M., Kullmer, U., Hackethal, A., Franke, F.E., Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control 19 (2008), 909–916.
20. [20] McCourt, C.K., Mutch, D.G., Gibb, R.K., et al. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol. Oncol. 104 (2007), 535–539.
21. [21] Pavelka, J.C., Ben-Shachar, I., Fowler, J.M., et al. Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients. Gynecol. Oncol. 95 (2004), 588–592.
22. [22] Ward, K.K., Shah, N.R., Saenz, C.C., McHale, M.T., Alvarez, E.A., Plaxe, S.C., Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol. Oncol. 126 (2012), 176–179.
23. [23] Creasman, W.T., Odicino, F., Maisonneuve, P., et al. Carcinoma of the corpus uteri. Int. J. Gynaecol. Obstet. 83:Suppl. 1 (2003), 79–118.
24. [24] Arem, H., Park, Y., Pelser, C., et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J. Natl. Cancer Inst. 105 (2013), 342–349.
25. [25] Risinger, J.I., Berchuck, A., Kohler, M.F., Watson, P., Lynch, H.T., Boyd, J., Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 53 (1993), 5100–5103.
26. [26] Duggan, B.D., Felix, J.C., Muderspach, L.I., Tourgeman, D., Zheng, J., Shibata, D., Microsatellite instability in sporadic endometrial carcinoma. J. Natl. Cancer Inst. 86 (1994), 1216–1221.
27. [27] Caduff, R.F., Johnston, C.M., Svoboda-Newman, S.M., Poy, E.L., Merajver, S.D., Frank, T.S., Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am. J. Pathol. 148 (1996), 1671–1678.
28. [28] Risinger, J.I., Hayes, A.K., Berchuck, A., Barrett, J.C., PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57 (1997), 4736–4738.
29. [29] Enomoto, T., Inoue, M., Perantoni, A.O., Terakawa, N., Tanizawa, O., Rice, J.M., K-ras activation in neoplasms of the human female reproductive tract. Cancer Res. 50 (1990), 6139–6145.
30. [30] Mizuuchi, H., Nasim, S., Kudo, R., Silverberg, S.G., Greenhouse, S., Garrett, C.T., Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res. 52 (1992), 2777–2781.
31. [31] Tashiro, H., Isacson, C., Levine, R., Kurman, R.J., Cho, K.R., Hedrick, L., p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150 (1997), 177–185.
32. [32] Lax, S.F., Kendall, B., Tashiro, H., Slebos, R.J., Hedrick, L., The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000), 814–824.
33. [33] Maxwell, G.L., Risinger, J.I., Gumbs, C., et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 58 (1998), 2500–2503.
34. [34] Sherman, M.E., Bur, M.E., Kurman, R.J., p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 26 (1995), 1268–1274.
35. [35] Alvarez, T., Miller, E., Duska, L., Oliva, E., Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?. Am. J. Surg. Pathol. 36 (2012), 753–761.
36. [36] Han, G., Sidhu, D., Duggan, M.A., et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod. Pathol. 26 (2013), 1594–1604.
37. [37] Mhawech-Fauceglia, P., Wang, D., Kesterson, J., et al. Gene expression profiles in stage 1 uterine serous carcinoma in comparison to grade 3 and grade 1 stage 1 endometrioid adenocarcinoma. PLoS One, 6, 2011, e18066.
38. [38] Ayeni, T.A., Bakkum-Gamez, J.N., Mariani, A., et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol. Oncol. 129 (2013), 478–485.
39. [39] Kandoth, C., Schultz, N., Cherniack, A.D., et al. Integrated genomic characterization of endometrial carcinoma. Nature 497 (2013), 67–73.
40. [40] Schultheis, A.M., Martelotto, L.G., De Filippo, M.R., Piscuglio, S., Ng, C.K., Hussein, Y.R., Reis-Filho, J.S., Soslow, R.A., Weigelt, B., TP53 mutational spectrum in endometrioid and serous endometrial cancers. Int. J. Gynecol. Pathol. 35 (2016), 289–300.
41. [41] Kurman, R.J., Carcangiu, M.L., Herrington, C.S., Young, R.H., (eds.) WHO Classification of Tumors of Female Reproductive Organs, 2014, IARC, Lyon, 125–135.
42. [42] Silverberg, S.G., De Giorgi, L.S., Clear cell carcinoma of the endometrium. Clinical, pathologic, and ultrastructural findings. Cancer 31 (1973), 1127–1140.
43. [43] Bae, H.S., Kim, H., Young Kwon, S., Kim, K.R., Song, J.Y., Kim, I., Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma?. Int. J. Gynecol. Pathol. 34 (2015), 74–84.
44. [44] Setiawan, V.W., Yang, H.P., Pike, M.C., et al. Type I and II endometrial cancers: have they different risk factors?. J. Clin. Oncol. 31 (2013), 2607–2618.
45. [45] Joehlin-Price, A.S., Perrino, C.M., Stephens, J., et al. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. Gynecol. Oncol. 133 (2014), 43–47.
46. [46] Geels, Y.P., Pijnenborg, J.M., van den Berg-van Erp, S.H., et al. Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis. Obstet. Gynecol. 120 (2012), 1124–1131.
47. [47] Gilks, C.B., Oliva, E., Soslow, R.A., Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am. J. Surg. Pathol. 37 (2013), 874–881.
48. [48] Soslow, R.A., Endometrial carcinomas with ambiguous features. Semin. Diagn. Pathol. 27 (2010), 261–273.
49. [49] Köbel, M., Meng, B., Hoang, L.N., et al. Molecular analysis of mixed endometrial carcinomas shows clonality in most cases. Am. J. Surg. Pathol. 40 (2016), 166–180.
50. [50] Silva, E.G., Deavers, M.T., Bodurka, D.C., Malpica, A., Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?. Int. J. Gynecol. Pathol. 25 (2006), 52–58.
51. [51] Rauh-Hain, J.A., Diver, E., Meyer, L.A., et al. Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: analysis of the National Cancer Database. Gynecol. Oncol. 139 (2015), 77–83.
52. [52] Rauh-Hain, J.A., Starbuck, K.D., Meyer, L.A., et al. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis. Gynecol. Oncol. 139 (2015), 84–89.
53. [53] Liu, J., Westin, S.N., Rational selection of biomarker driven therapies for gynecologic cancers: the more we know, the more we know we don't know. Gynecol. Oncol. 141 (2016), 65–71.
54. [54] Felix, A.S., Weissfeld, J.L., Stone, R.A., et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 21 (2010), 1851–1856.
55. [55] Brinton, L.A., Felix, A.S., McMeekin, D.S., et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol. Oncol. 129 (2013), 277–284.
56. [56] Sherman, M.E., Sturgeon, S., Brinton, L.A., et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod. Pathol. 10 (1997), 963–968.
57. [57] Yang, H.P., Wentzensen, N., Trabert, B., et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am. J. Epidemiol. 177 (2013), 142–151.
58. [58] Martínez, M.E., Cruz, G.I., Brewster, A.M., Bondy, M.L., Thompson, P.A., What can we learn about disease etiology from case-case analyses? Lessons from breast cancer. Cancer Epidemiol. Biomark. Prev. 19 (2010), 2710–2714.
59. [59] Brinton, L.A., Trabert, B., Anderson, G.L., et al. Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol. Biomark. Prev. 25 (2016), 1081–1089.
60. [60] Yang, H.P., Cook, L.S., Weiderpass, E., et al. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). Br. J. Cancer 112 (2015), 925–933.
61. [61] Trabert, B., Wentzensen, N., Felix, A.S., Yang, H.P., Sherman, M.E., Brinton, L.A., Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database. Cancer Epidemiol. Biomark. Prev. 24 (2015), 261–267.
62. [62] Brasky, T.M., Moysich, K.B., Cohn, D.E., White, E., Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. Gynecol. Oncol. 128 (2013), 113–119.
63. [63] Felix, A.S., Gaudet, M.M., La Vecchia, C., et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int. J. Cancer 136 (2015), E410–E422.
64. [64] Murali, R., Soslow, R.A., Weigelt, B., Classification of endometrial carcinoma: more than two types. Lancet Oncol. 15 (2014), e268–e278.
65. [65] Talhouk, A., McConechy, M.K., Leung, S., et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 113 (2015), 299–310.
66. [66] Stelloo, E., Nout, R.A., Osse, E.M., et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 22 (2016), 4215–4224.